To date, Madam Therapeutics and her academic partners have raised over 9 million Euro’s ‘non-dilutive funding’ (subsidies and investments by the founders) for the development of our platform of patented SAAP based products, with successful in-vitro results.
To enable the first clinical trials Madam Therapeutics is currently raising funds.
Investments in our company will help to prove our patented SAAP-148 can be applied as treatment against resistant bugs and solve one of the biggest societal challenges: antimicrobial resistance (such as MRSA)
For info or to get a copy of our investment information package, contact:
Remko van Leeuwen
+31 71 2040 105 Extension 100